NASDAQ · Manufacturing · Surgical & medical instruments & apparatus
$80.19−$2.33 (−2.82%) on the dayAs of the close; data may be delayed.
DXCM price, last 12 months
$92.34$54.84$80.19
Daily closes over the last 260 trading sessions: +45.8%. Highest close $92.34 on , lowest $54.84 on . Market data may be delayed.
Key stats
Previous close
$82.52
Open
$83.09
Day range
$79.17 – $83.09
52-week range
$56.72 – $92.59
Volume
4.5M
Avg volume (20 days)
4.7M
Market cap
$31.1B
Performance
1W−5.0%
1M+1.1%
3M−13.1%
6M+9.8%
YTD+19.3%
1Y+32.5%
vs S&P 500, 1Y+27.9 pts
Technicals and fundamentals
About DexCom, Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Chart DXCM with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full DXCM chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)3.6%average true range, % of price
52w low $56.7252w high $92.59
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)30.21.33x Manufacturing median (22.6)
P/E (forward)25.6
PEG1.30
Price / sales5.86
Price / book11.80
EV / EBITDA—
P/E since Jun 125.4 – 34.8
Company figures as of Nov 19, 2026.
Analysts
ConsensusStrong buy1.3 on 1 (strong buy) to 5 (strong sell)
Analysts26
Average target$98.58+24.6% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Jan 11, 2027 (in 52 days)A year after its Jan 12, 2026 results release; the last came Oct 29, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
No dividends on record.
Splits
Jun 13, 20224-for-1
Seasonality
-1.1
J
-0.6
F
+2.3
M
-4.9
A
+1.4
M
-0.4
J
-3.3
J
-2.8
A
-5.8
S
+7.7
O
+7.3
N
+0.9
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
+10
+1
−14
−5
+24
−9
+24
+9
−5
−5
+24%
2025
+12
+2
−23
+5
+20
+2
−7
−7
−11
−13
+9
+5
−15%
2024
−2
−5
+21
−8
−7
−5
−40
+2
−3
+5
+11
−0
−37%
2023
−5
+4
+5
+4
−3
+10
−3
−19
−8
−5
+30
+7
+10%
2022
−20
−4
+24
−20
−27
+0
+10
+0
−2
+50
−4
−3
−16%
2021
+14
−10
−5
−2%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Dexcom is mentioned as a competitor in the continuous glucose monitoring space but has no current continuous ketone monitoring products or approvals. The company may face competitive pressure as the market evolves toward dual-analyte monitoring.
Listed among key digital health providers in a market experiencing significant growth driven by chronic disease management demand and wearable sensor maturation, areas where Dexcom has established expertise.
Dexcom's G6 and G7 continuous glucose monitoring systems were key components of the successful Kaleido system evaluated in the study, contributing to the strong glycemic control outcomes and high sensor wear rates (98% median).
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.